Cefiderocol for severe carbapenem-resistant a. Baumannii pneumonia: Towards the comprehension of its place in therapy

Emanuele Rando; Francesco Vladimiro Segala; Joel Vargas; Cristina Seguiti; Gennaro De Pascale; Rita Murri; Massimo Fantoni

doi:10.3390/antibiotics11010003

Cefiderocol for severe carbapenem-resistant a. Baumannii pneumonia: Towards the comprehension of its place in therapy

Emanuele Rando, Francesco Vladimiro Segala, Joel Vargas, Cristina Seguiti, Gennaro De Pascale, Rita Murri, Massimo Fantoni

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospectively included patients with CRAB pneumonia hospitalized at Fondazione Policlinico Universitario Agostino Gemelli Hospital treated with cefiderocol either in the general ward or the intensive care unit. A total of 11 patients out of 13 had ventilator-associated pneumonia caused by CRAB, and 12/13 patients had polymicrobial infection. We found a 30-day success rate of 54%. Cefiderocol may have a role when facing severe XDR A. baumannii pneumonia. Future studies are warranted to better define its place in therapy in CRAB infections.

Lingua originale	English
pagine (da-a)	3-7
Numero di pagine	5
Rivista	Antibiotics
Volume	11
DOI	https://doi.org/10.3390/antibiotics11010003
Stato di pubblicazione	Pubblicato - 2022

Keywords

A. baumannii
CRAB
Cefiderocol
Pneumonia

Accesso al documento

10.3390/antibiotics11010003

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{36cb91f30d7e48d19496bfcd4c8aad94,

title = "Cefiderocol for severe carbapenem-resistant a. Baumannii pneumonia: Towards the comprehension of its place in therapy",

abstract = "Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospectively included patients with CRAB pneumonia hospitalized at Fondazione Policlinico Universitario Agostino Gemelli Hospital treated with cefiderocol either in the general ward or the intensive care unit. A total of 11 patients out of 13 had ventilator-associated pneumonia caused by CRAB, and 12/13 patients had polymicrobial infection. We found a 30-day success rate of 54%. Cefiderocol may have a role when facing severe XDR A. baumannii pneumonia. Future studies are warranted to better define its place in therapy in CRAB infections.",

keywords = "A. baumannii, CRAB, Cefiderocol, Pneumonia, A. baumannii, CRAB, Cefiderocol, Pneumonia",

author = "Emanuele Rando and Segala, {Francesco Vladimiro} and Joel Vargas and Cristina Seguiti and {De Pascale}, Gennaro and Rita Murri and Massimo Fantoni",

year = "2022",

doi = "10.3390/antibiotics11010003",

language = "English",

volume = "11",

pages = "3--7",

journal = "Antibiotics",

issn = "2079-6382",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

}

TY - JOUR

T1 - Cefiderocol for severe carbapenem-resistant a. Baumannii pneumonia: Towards the comprehension of its place in therapy

AU - Rando, Emanuele

AU - Segala, Francesco Vladimiro

AU - Vargas, Joel

AU - Seguiti, Cristina

AU - De Pascale, Gennaro

AU - Murri, Rita

AU - Fantoni, Massimo

PY - 2022

Y1 - 2022

N2 - Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospectively included patients with CRAB pneumonia hospitalized at Fondazione Policlinico Universitario Agostino Gemelli Hospital treated with cefiderocol either in the general ward or the intensive care unit. A total of 11 patients out of 13 had ventilator-associated pneumonia caused by CRAB, and 12/13 patients had polymicrobial infection. We found a 30-day success rate of 54%. Cefiderocol may have a role when facing severe XDR A. baumannii pneumonia. Future studies are warranted to better define its place in therapy in CRAB infections.

AB - Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospectively included patients with CRAB pneumonia hospitalized at Fondazione Policlinico Universitario Agostino Gemelli Hospital treated with cefiderocol either in the general ward or the intensive care unit. A total of 11 patients out of 13 had ventilator-associated pneumonia caused by CRAB, and 12/13 patients had polymicrobial infection. We found a 30-day success rate of 54%. Cefiderocol may have a role when facing severe XDR A. baumannii pneumonia. Future studies are warranted to better define its place in therapy in CRAB infections.

KW - A. baumannii

KW - CRAB

KW - Cefiderocol

KW - Pneumonia

KW - A. baumannii

KW - CRAB

KW - Cefiderocol

KW - Pneumonia

UR - http://hdl.handle.net/10807/232153

U2 - 10.3390/antibiotics11010003

DO - 10.3390/antibiotics11010003

M3 - Article

SN - 2079-6382

VL - 11

SP - 3

EP - 7

JO - Antibiotics

JF - Antibiotics

ER -

Cefiderocol for severe carbapenem-resistant a. Baumannii pneumonia: Towards the comprehension of its place in therapy

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo